Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
Want to see CPIX full AI Analyst Report?
CPIX Stock Chart & Stats
$4.72
-$0.13(-5.49%)
At close: 4:00 PM EST
$4.72
-$0.13(-5.49%)
Day’s Range― - ―
52-Week Range$1.85 - $6.61
Previous CloseN/A
Volume23.17K
Average Volume (3M)27.29K
Market Cap
$85.70M
Enterprise Value$83.12M
Total Cash (Recent Filing)$11.01M
Total Debt (Recent Filing)$10.07M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding14,983,107
10 Day Avg. Volume30,352
30 Day Avg. Volume27,288
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)2.39
Price to Sales (P/S)1.34
P/FCF Ratio12.31
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.98
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda-45.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsProduct-level gross margins near 83–85% indicate strong unit economics that persist across sales cycles. These margins provide durable cash conversion per sale, help absorb SG&A or development costs, and make the marketed assets attractive for partnerships or divestiture value.
Transformational Strategic TransactionThe $100M cash sale plus inventory and transition fees would materially strengthen the balance sheet and shift commercial expenses to Apotex. This structural change reduces operating burn, funds development priorities, and converts recurring commercial risk into capital that can support pipeline execution.
Advanced Clinical Program (ifetroban)Ifetroban's large safety database, Fast Track and orphan designations accelerate regulatory pathways and increase program value. A mature safety dataset and active Phase II trials materially raise the probability of partnering, milestone revenue, or successful development-focused refocus.
Bears Say
Persistent UnprofitabilityCumberland has sustained operating and net losses with TTM profitability deteriorating to roughly -17%, producing negative ROE. Ongoing losses can erode equity, constrain reinvestment, and require either asset sales, dilution, or continued reliance on non-recurring transactions to stabilize finances.
Inconsistent Cash GenerationFree cash flow has swung materially and declined steeply versus prior periods, reflecting inconsistent cash conversion. Variable FCF limits the firm's ability to fund trials and operations organically and increases dependency on transaction proceeds or financing to bridge development milestones.
Revenue Base Reduction & Strategic PivotDivesting the marketed portfolio and stepping away from double-digit revenue targets reduces recurring revenue and commercial capability. The shift toward a development-stage, orphan-focused model raises binary trial risk and increases reliance on milestone/licensing outcomes for future revenue.
Cumberland Pharmaceuticals News
CPIX FAQ
What was Cumberland Pharmaceuticals Inc’s price range in the past 12 months?
Cumberland Pharmaceuticals Inc lowest stock price was $1.85 and its highest was $6.61 in the past 12 months.
What is Cumberland Pharmaceuticals Inc’s market cap?
Cumberland Pharmaceuticals Inc’s market cap is $85.70M.
When is Cumberland Pharmaceuticals Inc’s upcoming earnings report date?
Cumberland Pharmaceuticals Inc’s upcoming earnings report date is Aug 11, 2026 which is in 51 days.
How were Cumberland Pharmaceuticals Inc’s earnings last quarter?
Cumberland Pharmaceuticals Inc released its earnings results on May 05, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.22.
Is Cumberland Pharmaceuticals Inc overvalued?
According to Wall Street analysts Cumberland Pharmaceuticals Inc’s price is currently Overvalued.
Does Cumberland Pharmaceuticals Inc pay dividends?
Cumberland Pharmaceuticals Inc does not currently pay dividends.
What is Cumberland Pharmaceuticals Inc’s EPS estimate?
Cumberland Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cumberland Pharmaceuticals Inc have?
Cumberland Pharmaceuticals Inc has 14,983,107 shares outstanding.
What happened to Cumberland Pharmaceuticals Inc’s price movement after its last earnings report?
Cumberland Pharmaceuticals Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.956%.
Which hedge fund is a major shareholder of Cumberland Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CPIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cumberland Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
168.75%
12-Months-Change
Fundamentals
Return on Equity
-28.75%
Trailing 12-Months
Asset Growth
1.51%
Trailing 12-Months
Company Description
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
CPIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful strategic progress: a transformational $100M acquisition agreement that unlocks near-term value, regulatory wins (expanded Caldolor label and facility clearance), commercialization progress (Talicia promotion, Vibativ China shipment) and an encouraging development pipeline (ifetroban with Fast Track and robust safety data). These positives are tempered by a modest Q1 revenue base, a GAAP net loss (~$3.3M) and limited cash on hand until the transaction closes, plus the company’s deliberate pivot away from pursuing double-digit revenue growth in 2026. On balance, the call emphasizes value realization and a clear strategic plan to focus on development, with the transaction expected to materially strengthen the balance sheet and reduce operating expense burden—leading to a favorable overall tone.View all CPIX earnings summariesTechnical Analysis
Ownership Overview
41.60% Insiders
4.94% Mutual Funds
6.88% Other Institutional Investors
43.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---